We are live on
!
Find out more
WCA
Waypoint Capital Advisors Portfolio holdings
AUM
$470M
1-Year Est. Return
32.8%
This Fund
S&P 500
This Quarter
Est. Return
+7.23%
1 Year Est. Return
+32.8%
3 Year Est. Return
+50.26%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$18.5M
(+6.4%)
Cap. Flow
+$1.91M
Cap. Flow
% of AUM
0.62%
Top 10 Holdings %
Top 10 Hldgs %
38.05%
Holding
139
New
10
Increased
26
Reduced
46
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$1.15M |
| 2 |
Vanguard Growth ETF
VUG
|
+$1.12M |
| 3 |
Vanguard Value ETF
VTV
|
+$1.08M |
| 4 |
Dimensional International Core Equity 2 ETF
DFIC
|
+$943K |
| 5 |
Dimensional US Core Equity Market ETF
DFAU
|
+$819K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$1.92M |
| 2 |
Sysco
SYY
|
+$1.83M |
| 3 |
Bridgewater Bancshares
BWB
|
+$710K |
| 4 |
LAZR
Luminar Technologies
LAZR
|
+$495K |
| 5 |
Schwab International Equity ETF
SCHF
|
+$333K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.22% |
| 2 | Technology | 6.77% |
| 3 | Industrials | 5.97% |
| 4 | Consumer Staples | 3.05% |
| 5 | Consumer Discretionary | 2.71% |
Similar funds
SIGI
FPFS
VCMC
SFP
EDRIA
MRCM
AC
NIC
Waypoint Capital Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Waypoint Capital Advisors held 139 positions worth $307M, up 6.4% from $289M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Waypoint Capital Advisors's Q1 2023 filing shows 10 new, 26 increased, 46 reduced and 6 closed positions. Its largest new stake was Dimensional US Core Equity Market ETF: 28,974 shares worth $834K. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $1.92M.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 12% a quarter earlier, followed by Technology and Industrials.
- Waypoint Capital Advisors's largest Q1 2023 buy was Dimensional US Core Equity Market ETF: 28,974 shares worth $834K.
- Waypoint Capital Advisors added most to Revance Therapeutics, Inc. in Q1 2023, an estimated $1.15M increase.
- Waypoint Capital Advisors's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $1.92M.
- Waypoint Capital Advisors fully exited Sysco in Q1 2023, selling an estimated $1.83M.
- Waypoint Capital Advisors's ten largest holdings make up 38% of its $307M portfolio in Q1 2023.
- Waypoint Capital Advisors opened 10 new positions and closed 6 in Q1 2023.
- Waypoint Capital Advisors's portfolio value rose 6.4% quarter-over-quarter to $307M.
Based on Waypoint Capital Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.